Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FYN | P06241 | 6/20 | 0.57 |
| ▸ | SRC | P12931 | 8/20 | 0.53 |
| ▸ | EGFR | P00533 | 4/20 | 0.52 |
| ▸ | BTK | Q06187 | 2/20 | 0.52 |
| ▸ | LCK | P06239 | 1/20 | 0.52 |
| ▸ | JAK3 | P52333 | 1/20 | 0.52 |
| ▸ | ITK | Q08881 | 1/20 | 0.52 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.51 |
| ▸ | PRKDC | P78527 | 2/20 | 0.51 |
| ▸ | ABL1 | P00519 | 1/20 | 0.51 |
| ▸ | MAP2K5 | Q13163 | 1/20 | 0.50 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.50 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.50 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15826974 | 0.84 | FYN (0.54) | FYNSRCEGFRBTKLCK | |
| SCHEMBL17320669 | 0.81 | BTK (0.58) | FYNSRCEGFRBTKLCK | |
| SCHEMBL15826968 | 0.81 | PIK3CD (0.73) | FYNSRCEGFRBTKPIK3CD | |
| SCHEMBL14471386 | 0.80 | PIK3CD (0.63) | FYNSRCEGFRBTKPIK3CD | |
| SCHEMBL13183365 | 0.79 | SRC (0.57) | FYNSRCEGFRBTKLCK | |
| SCHEMBL14471387 | 0.78 | SRC (0.64) | FYNSRCEGFRBTKLCK | |
| SCHEMBL14471393 | 0.78 | SRC (0.73) | FYNSRCEGFRBTKLCK | |
| SCHEMBL15826975 | 0.77 | FYN (0.68) | FYNSRCEGFRBTKPIK3CD | |
| SCHEMBL14472337 | 0.77 | HDAC1 (0.52) | FYNSRCEGFRBTKLCK | |
| SCHEMBL14086355 | 0.76 | SRC (0.66) | FYNSRCEGFRPIK3CDPRKDC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160045503-A1 | FORMULATIONS CONTAINING REVERSIBLE COVALENT COMPOUNDS | PRINCIPIA BIOPHARMA INC. | 2016-02-18 | — | — | US | disclosed |
| US-20150353562-A1 | TYROSINE KINASE INHIBITORS | PRINCIPIA BIOPHARMA INC. (US) | 2015-12-10 | — | — | US | disclosed |
| US-20150353557-A1 | TYROSINE KINASE INHIBITORS | PRINCIPIA BIOPHARMA INC. (US) | 2015-12-10 | — | — | US | disclosed |
| US-8962831-B2 | Tyrosine kinase inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2015-02-24 | — | — | US | disclosed |
| US-8962635-B2 | Tyrosine kinase inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2015-02-24 | — | — | US | disclosed |
| US-20140303190-A1 | TYROSINE KINASE INHIBITORS | PRINCIPIA BIOPHARMA INC. (US) | 2014-10-09 | — | — | US | disclosed |
| US-8759358-B1 | Tyrosine kinase inhibitors | PRINCIPIA BIOPHARMA INC. (US) | 2014-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150353557-A1 | TYROSINE KINASE INHIBITORS | BMX, ITK, BLK | FYN 28/4885SRC 18/4885EGFR 21/4885 |
| US-20150353562-A1 | TYROSINE KINASE INHIBITORS | BMX, ITK, BLK | FYN 28/4885SRC 18/4885EGFR 21/4885 |
| US-20160045503-A1 | FORMULATIONS CONTAINING REVERSIBLE COVALENT COMPOUNDS | PTMS, SSB, HDAC6 | FYN 891/4885SRC 1547/4885EGFR 3358/4885 |
| US-20140303190-A1 | TYROSINE KINASE INHIBITORS | BMX, ITK, BLK | FYN 28/4885SRC 18/4885EGFR 21/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.